Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine

In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquire...

Descripción completa

Detalles Bibliográficos
Autores principales: Basile, Kerri, Rockett, Rebecca J., McPhie, Kenneth, Fennell, Michael, Johnson-Mackinnon, Jessica, Agius, Jessica E., Fong, Winkie, Rahman, Hossinur, Ko, Danny, Donavan, Linda, Hueston, Linda, Lam, Connie, Arnott, Alicia, Chen, Sharon C.-A., Maddocks, Susan, O’Sullivan, Matthew V., Dwyer, Dominic E., Sintchenko, Vitali, Kok, Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501619/
https://www.ncbi.nlm.nih.gov/pubmed/36146829
http://dx.doi.org/10.3390/v14092023
Descripción
Sumario:In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.

Ejemplares similares